Stocks in play: BriaCell Therapeutics Corp.
Announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in nine cases as of their last assessment. BriaCell Therapeutics Corp. shares T.BCT are trading up $0.05 at $6.43.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.